Review ArticlesRadiomics, Radiogenomics, and Next-Generation Molecular Imaging to Augment Diagnosis of Hepatocellular CarcinomaBell, Meghan BS*; Turkbey, Evrim B. MD†; Escorcia, Freddy E. MD, PhD*Author Information From the *Laboratory of Molecular Radiotherapy, Molecular Imaging Program, Radiation Oncology Branch, National Cancer Institute †Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD. M.B. and E.B.T. contributed equally to this work. This work was supported in part by NIH ZIA BC 011800. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Freddy E. Escorcia, MD, PhD, Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20814. E-mail: firstname.lastname@example.org. 240-858-3062. The Cancer Journal: March/April 2020 - Volume 26 - Issue 2 - p 108-115 doi: 10.1097/PPO.0000000000000435 Buy Metrics Abstract Ultrasound, computed tomography, magnetic resonance imaging, and [18F]F-fluorodeoxyglucose positron emission tomography are invaluable in the clinical evaluation of human cancers. Radiomics and radiogenomics tools may allow clinicians to standardize interpretation of these conventional imaging modalities, while better linking radiographic hallmarks to disease biology and prognosis. These advances, coupled with next-generation positron emission tomography imaging tracers capable of providing biologically relevant tumor information, may further expand the tools available in our armamentarium against human cancers. We present current imaging methods and explore emerging research that may improve diagnosis and monitoring of local, oligometastatic, and disseminated cancers exhibiting heterogeneous uptake of [18F]F-fluorodeoxyglucose, using hepatocellular carcinoma as an example. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.